NASDAQ:SLS
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. reported net income of −$26.9M in fiscal 2025. The diluted share count rose 78.2%.Summary generated from SELLAS Life Sciences Group, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−66.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+78.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8 | 1 | 0 | n/a | n/a |
| Operating income | −25 | −42 | −38 | −32 | −28 |
| Net income | −21 | −41 | −37 | −31 | −27 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KResults of operations and financial condition
Aug 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Jul 27, 2026 - 8-KDirector or officer change
Jun 25, 2026 - 8-KResults of a shareholder vote
Jun 18, 2026 - 4Insider transaction report
Jun 18, 2026 - 8-KOther events
Jun 2, 2026 - 8-KResults of operations and financial condition
May 12, 2026